Krystexxa Plus Methotrexate Approved for Uncontrolled Gout
The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in 152 adults with uncontrolled gout.
The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in 152 adults with uncontrolled gout.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
Increased uric acid excretion could explain, at least in part, the renoprotective effects of SGLT2 inhibitors.
In-hospital mortality rate lower for patients with acute heart failure exacerbation who received colchicine for gout flare
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
A review of regulatory and drug development status updates.
The sBLA submission is supported by data from the phase 4 MIRROR trial.
Allopurinol initiation, achieving target serum urate levels, allopurinol dose escalation not associated with increased mortality
The sBLA submission is supported by data from the phase 4 MIRROR trial.
ALLN-346 is an investigational, first-in-class, nonabsorbed, orally-administered enzyme that breaks down urate in the gastrointestinal tract.